Biology Section

Home | Research & Innovation | Scientific Programmes | Experimental Therapeutics Programme | Biology Section

Post-Doctoral Fellows

  • María Elena Hernández


  • Mª Isabel Albarrán
  • Antonio Cebriá
  • Elena Gómez-Casero
  • Javier Klett
  • María Martín
  • Mª del Carmen Rodríguez de Miguel

The early Drug Discovery (eDD) process encompasses screening campaigns for hit identification, hit generation and hit lo lead and lead optimisation phases, in order to end up with a lead compound able to demonstrate in vivo proof-of-concept. ADME, an acronym for absorption, distribution, metabolism and excretion, describes the disposition of a pharmaceutical compound within an organism. ADME properties influence the drug levels and the kinetics of drug exposure to the tissues, and hence influence the performance and pharmacological activity of the compound as a drug. It is fundamental to assess the parameters for ADME properties early on during the discovery stage, since they provide critical information that can help to better interpret the screening results and to design new molecules. Drug-like properties should be optimised in parallel to pharmacological activity against the target. For that reason, we perform ADME characterisation of the compounds during the initial steps of eDD projects and we carry out PK, PK/PD and distribution studies to validate the drug properties of our advanced molecules.